@BioSignal BioSignal
BioSignal posts on X about china, eli lilly, $lly, this is the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [-----] -47%
- [--] Month [------] +255%
Mentions: [--] #
- [--] Week [--] -9.10%
- [--] Month [---] -14%
Followers: [---] #
- [--] Week [---] +3.10%
- [--] Month [---] +65%
CreatorRank: [---------] #
Social Influence
Social category influence stocks 55.45% finance 31.82% countries 24.55% currencies 7.27% technology brands 6.36% travel destinations 4.55% cryptocurrencies 2.73% ncaa football 0.91% social networks 0.91% vc firms 0.91%
Social topic influence china 23.64%, eli lilly 12.73%, $lly 10.91%, this is 10%, the first 8.18%, science 8.18%, just a 7.27%, $legn 6.36%, legn 6.36%, $bmy 6.36%
Top accounts mentioned or mentioned by @jikkyleaks @grok @drno_reformed @charlotteoworld @barraobeirgin @bruce_kris56597
Top assets mentioned Eli Lilly and Company (LLY) Legend Biotech Corp (LEGN) Bristol-Myers Squibb Co (BMY) Merck & Co., Inc. (MRK) AstraZeneca PLC (AZN) Gilead Sciences, Inc. (GILD) Novo-Nordisk (NVO) Sanofi (SNY) AbbVie Inc (ABBV) Pfizer, Inc. (PFE) Novartis AG (NVS) Synthetify (SNY) Johnson & Johnson (JNJ) Immix Biopharma, Inc. (IMMX) Kyverna Therapeutics, Inc. (KYTX) Amgen, Inc. (AMGN) Structure Therapeutics Inc. (GPCR) Recursion Pharmaceuticals, Inc. (RXRX) Schrodinger, Inc. (SDGR) Taysha Gene Therapies, Inc. (TSHA)
Top Social Posts
Top posts by engagements in the last [--] hours
"The "Battle for Bone Marrow" was the main event at ASH [----]. The Multiple Myeloma (MM) CAR-T market is evolving from a one-horse race into a three-front war. Here is the landscape assessment for investors: [--]. The King: Legend Biotech / J&J ($LEGN / $JNJ) Carvykti is still the gold standard. Data: mPFS [----] months in late-line patients. This durability is absurd. It sets a massive moat for anyone trying to displace them based on efficacy alone. [--]. The Challenger: Arcellx / Gilead ($ACLX / $GILD) Anito-cel is the immediate threat. Data: 96% ORR but the "Alpha" is safety. No delayed"
X Link 2025-12-14T21:42Z [---] followers, [---] engagements
"The data confirms it: China's Legend Biotech ($LEGN) is eating Bristol Myers Squibb's lunch. Their asset Carvykti is now the dominant BCMA CAR-T leaving Abecma behind with superior efficacy and 112% YoY growth. BMS's Counter-Move: They are pivoting to "Blue Ocean" markets. Monopoly: Just secured the only global approval for MZL (Marginal Zone Lymphoma) with Breyanzi. Tech Pivot: Dropped $1.5B on Orbital Therapeutics to lead the "In Vivo" (In-body manufacturing) revolution. Legend wins the current cycle. BMS is betting on the next one. $LEGN $BMY $JNJ $GILD $XBI $IBB"
X Link 2025-12-16T14:29Z [---] followers, [---] engagements
"The headline is the $888M deal with Servier. But the "Alpha" is hidden in the efficiency metrics just released by Insilico Medicine. If you are trading AI Biotech ($RXRX $SDGR) look at this data point: Why did Servier pay up Speed: Insilico hits PCC in [---] years vs the industry average of [---] years. Efficiency: They only synthesize 60-200 molecules per project to find a hit. This isn't just a partnership; it's a validation of superior unit economics. Servier is betting that Generative AI is the only way to fix the broken R&D ROI model. $RXRX $SDGR $EXAI $XBI $IBB"
X Link 2026-01-07T02:15Z [---] followers, [---] engagements
"BREAKING: Taysha Gene Therapies ($TSHA) just secured a massive regulatory win for Rett Syndrome. They have achieved alignment with the FDA on TSHA-102 (AAV9 gene therapy). The "Alpha" here is Extrapolation: The FDA agreed that efficacy data from adolescents/adults can support a BLA approval for children as young as [--] years old. Why this is a market mover: Speed: Bypasses the need for a lengthy separate pediatric Phase [--] before launch. TAM Expansion: Immediate access to the full prevalence pool (est. 15k-20k patients) upon approval. Differentiation: Unlike Acadias ($ACAD) chronic treatment"
X Link 2026-01-09T22:15Z [---] followers, [---] engagements
"The Anxiety (GAD) market has been stuck on SSRIs for [--] years. Luye Pharma just changed the game. The Alpha: China has 58M anxiety patients relying on 2006-era drugs (like $LLY's Cymbalta). Luye Pharma just filed for the first GAD innovation in two decades: Toludesvenlafaxine. This is an SNDRI (Serotonin + Norepinephrine + Dopamine). By adding Dopamine they achieved: 50% Remission Rates Minimized the #1 cause of patient dropouts (Sexual side effects). This is the "Holy Grail" mechanism Western CNS biotechs like $AXSM have been chasing. Luye is executing. $AXSM $LLY $XBI $IBB"
X Link 2026-01-13T15:30Z [---] followers, [---] engagements
"SMART MONEY ALERT: ShiZe Biotherapeutics just secured 400M ($55M) to win the race for a Parkinson's cure. The backers are a "Who's Who" of biotech: Lilly Asia Ventures Sequoia China Qiming and led by 3SBio ($1530.HK). The Asset: XS411. An "Off-the-shelf" (Allogeneic) iPSC-derived dopaminergic neuron therapy. The Alpha (Data Update): This isn't just a paper tiger. They have dosed [--] patients in China. PET scans confirm new dopamine cell survival in the putamen. Significant reduction in "OFF" time (periods where standard meds fail). FDA & NMPA dual clearance for trials. While Western investors"
X Link 2026-01-16T11:00Z [---] followers, [--] engagements
"The IBD market is witnessing a convergence of its two most valuable mechanisms. We know IL-23 is the King (see $ABBV Skyrizi). We know TL1A is the Prince (see $MRK buying Prometheus $RHHBY buying Televant). But what if you combined them Caldera Therapeutics just launched with a massive $112.5M Series A to answer that question. They have dosed the first patient with CLD-423 a First-in-Class Bispecific Antibody targeting both IL-23 and TL1A. The Alpha is the origin: This asset wasn't found in Boston. It was invented in China by Qyuns Therapeutics ($02509.HK). Qyuns utilized the "NewCo""
X Link 2026-01-16T22:15Z [---] followers, [---] engagements
"Everyone is looking at ImmunityBios ($IBRX) 700% revenue explosion from Anktiva. But you missed the real signal buried in the report: CAR-NK is back from the dead. For years Wall Street treated "Off-the-Shelf" NK cells like toxic waste (look at $FATE -98%). The problem was always durability. The cells didn't last. $IBRX just flipped that narrative. Their CD19 CAR-NK + Rituximab posted a Complete Response (CR) lasting 15+ months in WM. Here is the "China Edge" that validates this isn't a fluke: While the West abandoned NK cells Chinese biotechs pivoted them into Autoimmune Disease (Lupus/SLE)."
X Link 2026-01-21T05:00Z [---] followers, [---] engagements
"Most investors are too focused on Multiple Myeloma to notice this outlier. Immix Biopharma just confirmed a [----] BLA filing for NXC-201 and the efficacy gap is massive. The data breakdown: Indication: AL Amyloidosis (Relapsed/Refractory). Efficacy: 15/20 patients achieved CR. With pending data this could hit 95%. The Alpha: 0% Neurotoxicity. Why this matters: Zero neurotoxicity + 1-day median CRS means this can be an Outpatient CAR-T. While $JNJ and $BMY are stuck with expensive hospital stays for their BCMA therapies Immix is building the first scalable outpatient model for this niche. $IMMX"
X Link 2026-01-22T11:00Z [---] followers, [--] engagements
"BREAKING: Legend Biotech just cemented its dominance in the CAR-T space. Carvykti generated $1.887 BILLION in global sales for [----] officially achieving "Blockbuster" status. While the revenue is massive for a Chinese biotech the "Alpha" is in the long-term data just released: 33% of late-stage (RR/MM) patients are progression-free at 5+ years. This was achieved with a single infusion and NO maintenance therapy. In the Multiple Myeloma landscape $LEGN (partnered with $JNJ) is rapidly eating market share from Bristol Myers Squibb ($BMY). With approval expanding to earlier lines of therapy the"
X Link 2026-01-24T15:30Z [---] followers, [---] engagements
"The "King Slayer" has arrived in the CAR-T War. 🩸 Chinese analysts are quietly sounding the alarm on their national champion Legend Biotech ($LEGN). The consensus Arcellx ($ACLX) isn't just a competitor; it's the "fixed" version of the drug. The Alpha (from the Chinese Report): While Legend's Carvykti generates $555M/quarter it suffers from a "Parkinson-like" delayed neurotoxicity risk. Arcellxs Anito-cel uses a novel "D-Domain" binder (Fast On/Off) that has resulted in [--] cases of delayed neurotoxicity in 150+ patients. The "Kite" Moat: Its not just science; its logistics. Legend: [--] Day"
X Link 2026-01-27T02:15Z [---] followers, [---] engagements
"The "Engine Swap" that could reset the CAR-T sector. 🧬 Every FDA-approved CAR-T therapy on the market today ($NVS $GILD $BMY $LEGN) runs on the same chassis: The CD3 (Zeta) signaling chain. It works but it has two fatal flaws: High Toxicity (Cytokine Storms). T-Cell Exhaustion (Relapse). The Breakdown: Researchers at USC Keck just published a breakthrough in Science Translational Medicine that replaces the "old engine" (CD3) with a new one: ZAP327. They call it STEM CAR-T. The Alpha: In head-to-head mouse models vs. standard CAR-T: Safety: Significantly lower cytokine release (Solving the"
X Link 2026-01-27T05:00Z [---] followers, [---] engagements
"BREAKING: The $30B Mega-Merger is stalled. Merck ($MRK) has halted negotiations to acquire Revolution Medicines ($RVMD). The Deal Breaker: Price. Despite a rumored valuation of $30B (a massive premium over $RVMDs $22.7B cap) the parties could not bridge the gap. The Alpha: The Asset: Merck is chasing RMC-6236 (Pan-RAS Inhibitor) which has shown 100% ORR in early combos with Keytruda. The Desperation: Merck needs a solution for the [----] Keytruda patent cliff. The Trade: Volatility incoming. With talks paused $RVMD may dip but $ABBV (previously interested at $20B+) could re-enter the chat."
X Link 2026-01-27T08:00Z [---] followers, [----] engagements
"BREAKING: The race for the first Autoimmune CAR-T approval is officially entering the home stretch. Kyverna Therapeutics ($KYTX) just confirmed they will file for FDA approval (BLA) in H1 [----] for Stiff Person Syndrome. This puts them ahead of the pack but the competition is fierce: $BMY: Just initiated Phase [--] for Systemic Sclerosis (SSc) validating the modality with Big Pharma capital. $CABA: Targeting a [----] filing for Myositis; leveraging Cellares for automated manufacturing. $RNAC: The differentiatormRNA CAR-T requiring no chemotherapy conditioning. The "Alpha": With $BMY entering Phase"
X Link 2026-01-30T02:15Z [---] followers, [--] engagements
"The weekly GLP-1 dominance of Eli Lilly and Novo Nordisk is officially under threat. AstraZeneca ($AZN) just committed $18.5 billion to challenge the incumbents but they arent using a Western asset. They are betting the house on Chinas CSPC Pharmaceutical ($1093.HK). The Alpha: $1.2B upfront cash (largest in China biotech history). Dosing: Monthly injection (vs. $LLY / $NVO weekly). Lead Asset: SYH2082 (GLP-1R/GIPR) P1 ready. Tech: Proprietary LiquidGel delivery + AI peptide discovery. AZN previously paid $110M for CSPCs AI platform last year. Todays 10x jump in upfront payment signals that"
X Link 2026-01-31T08:00Z [---] followers, [---] engagements
"The "Manufacturing Nightmare" of cell therapy is about to end. Current CAR-T requires taking a patient's cells shipping them to a lab for weeks and then re-infusing them. CSPC Pharmaceutical ($1093.HK) just got NMPA approval to skip the lab entirely. SYS6055 is Chinas first "in vivo" CAR-T to enter clinical trials. Instead of engineering cells in a clean room it uses a lentiviral vector to turn a patients T-cells into cancer-killers directly in the bloodstream. Why this is the ultimate "Alpha" play: Cost: Could reduce the $400k price tag of Western CAR-T by 80%+. Access: No more specialized"
X Link 2026-01-31T11:00Z [---] followers, [---] engagements
"BREAKING: The FDA has halted Regenxbios ($RGNX) entire MPS gene therapy franchise after a patient developed a brain tumor. This is a "Black Swan" event for the AAV sector. A 5-year-old child treated with RGX-111 (MPS I) was found to have a CNS tumor [--] years post-dose. Genetic analysis revealed the AAV9 vector integrated directly into the PLAG1 proto-oncogenethe industrys worst-case "insertional mutagenesis" scenario. The fallout is immediate: RGX-121 (MPS II) PDUFA on Feb [--] is likely DOA. $700M in milestones from the Nippon Shinyaku deal are at risk. Serious "read-through" safety concerns for"
X Link 2026-01-31T15:30Z [---] followers, 71.9K engagements
"BREAKING: Regenxbio ($RGNX) has entered a regulatory tailspin as the FDA halts its entire MPS gene therapy franchise following a confirmed tumor in a Phase [--] patient. The Alpha: This isn't just a clinical delayit is a "Nightmare Scenario" for the AAV sector. A 5-year-old child treated with RGX-111 (MPS I) developed a brain tumor after the AAV9 vector integrated into the PLAG1 proto-oncogene. This confirms the long-feared risk of "insertional mutagenesis" that many bulls argued was negligible. The Immediate Fallout: RGX-121 (MPS II) PDUFA date on Feb [--] is effectively DOA; expect a CRL or"
X Link 2026-01-31T19:00Z [---] followers, [---] engagements
"The standard of care for AL Amyloidosisa devastating orphan disease with a 10% survival rate for non-respondersis about to be disrupted. While $JNJs Darzalex ($MRK/co-pay) redefined the market with a 53% CR nearly half of patients still face organ failure. Immix Biopharma ($IMMX) just secured FDA Breakthrough Therapy Designation (BTD) for NXC-201 making it the only BTD-designated therapy in active development for this $3B indication. The Alpha: Unprecedented Depth: 75% of patients achieved CR with potential to hit 95% as MRD- cases convert. Safety Leap: "Single-Day CRS" design with zero"
X Link 2026-02-02T05:00Z [---] followers, [--] engagements
"Luye Pharma ($02186(dot)HK) is walking a billion-dollar tightrope. To fund the spin-off of its oncology unit Nanjing Luye management just signed a "deal with the devil" involving aggressive profit targets and a ticking IPO clock. The "Alpha" here is the extreme pressure on Nanjing Luyes valuation. While theyve secured 285M RMB in fresh capital from Cinda the strings attached are heavy: If they don't IPO in [---] years Luye must buy back the stake at 9% annualized interest. They are banking on Zepzelca (Lurbinectedin) to drive growth but early China sales are stalling despite favorable insurance"
X Link 2026-02-02T22:15Z [---] followers, [--] engagements
"BREAKING: Genmab ($GMAB) just pulled the plug on GEN1286 (EGFR/c-Met ADC) marking the third clinical halt for assets acquired in the $1.8B ProfoundBio deal. The "house cleaning" is accelerating as Genmab pivots resources toward its newer $8B Merus ($MRUS) acquisition. The Alpha: This is a brutal "Buyer's Remorse" signal for the ADC sector. GEN1286 enrollment was halted at just [--] patients following the previous axing of GEN1160 (CD70) and GEN1107 (PTK7). Genmab is effectively cannibalizing the ProfoundBio pipeline in favor of Merus's multispecific platform. The implications for $GMAB"
X Link 2026-02-03T08:00Z [---] followers, [---] engagements
"The PD-1/VEGF bispecific arms race has reached its "mid-game" and the gap between the leader and the laggards is now measured in years not months. While Big Pharma titans ($MRK $PFE $ABBV) are just showing up to the party Akeso ($9926.HK) and Summit ($SMMT) have already cleared the dance floor. The "Alpha" is the sheer clinical inertia Akeso has built. Ivonescimab (AK112) started Ph1 in 2019roughly [--] years before Merck ($MRK) even got into the clinic with their own candidate (LM-299). By the time the laggards produce Ph3 data Ivonescimab will likely have established the "Standard of Care""
X Link 2026-02-03T15:30Z [---] followers, [--] engagements
"JUST IN: Shanghai Pharma announces it is divesting its 30% stake in Sino-American Shanghai Squibb (SASS) for $144M (RMB 1.02B). This marks a definitive exit from the historic joint venture with Bristol Myers Squibb. This is a strategic retreat by $BMY from older China JV structures as Western MNCs shift toward direct-to-market or NewCo models. The $480M total valuation for the JV highlights a major re-rating of legacy manufacturing and distribution assets in the region. Watch for a potential buyer announcement likely a domestic player looking to absorb $BMYs mature portfolio. $BMY $2607.HK"
X Link 2026-02-04T21:54Z [---] followers, [--] engagements
"BREAKING: Akeso ($9926.HK) just secured Priority Review for AK112 (Ivonescimab) in combination with docetaxel for advanced biliary tract cancer (BTC). This follows its massive momentum in NSCLC and direct competition with Merck's Keytruda. Simultaneously Bio-Thera ($688177.SH) and MediLinks B7-H3 ADC (YL201) received Priority Review for pre-treated SCLC Esophageal and Nasopharyngeal cancers. With Roche ($RHHBY) recently doubling down on YL201 with a $570M near-term payment deal this asset is now officially in a race with Daiichi Sankyo/Mercks ifinatamab deruxtecan. Alpha: The rapid regulatory"
X Link 2026-02-05T05:00Z [---] followers, [---] engagements
"The CDE progress report for Feb [----] confirms that the "China speed" in oncology is no longer just about fast-following; its about aggressive market capture. Akeso ($9926.HK) has pushed AK112 into Priority Review for Biliary Tract Cancer a tough-to-treat indication where it could beat Western giants to a first-line approval. Meanwhile BioNTech is going "all-in" on the China market filing INDs for its entire core trio: BNT327 (PD-L1/VEGF) BNT324 (B7-H3 ADC) and BNT326 (HER3 ADC). This is a direct challenge to the Daiichi/Merck and AstraZeneca pipeline dominance. Other key INDs to watch:"
X Link 2026-02-05T11:00Z [---] followers, [--] engagements
"Headline: While Wall Street debates the "persistence" of CAR-T China is scaling "Off-the-Shelf" NK cells at 1/10th the cost. The Tweet Text: Everyone is watching Western autologous CAR-T ($GILD $BMY). But China's Imbioray () just secured a 200M RMB Series B to scale its universal NK platform. Their lead asset IBR854 is a first-in-class 5T4-targeted "off-the-shelf" cell therapy already in Phase [--] for Renal Cell Carcinoma and NSCLC. If they hit their safety/efficacy endpoints the cost-advantage alone (10% of Western prices) will disrupt the global oncology pricing model. AI-integration via"
X Link 2026-02-06T19:00Z [---] followers, [--] engagements
"Is the era of "Boutique" CAR-T over New [----] data from Caribou Biosciences ($CRBU) suggests the answer is yes. Their off-the-shelf assets Vispa-cel and CB-011 just posted a massive 86% and 92% ORR respectively. Most importantly the 12-month durability is now "on par" with autologous giants like Yescarta ($GILD) and Abecma ($BMY). The investment shift here is about the "Total Cost of Care." Traditional CAR-T: $500k + Hospitalization + 4-week wait. CRBU Allogeneic: Projected $45k (300000 RMB) + Outpatient + Immediate dosing. Caribou's CRISPR-armoring (PD-1 knockout) is preventing the premature"
X Link 2026-02-07T11:00Z [---] followers, [---] engagements
"JUST IN: Henlius just secured a massive $388M deal with Japanese giant Eisai to commercialize their PD-1 Serplulimab in Japan. $75M upfront is a strong validation for a Chinese PD-1 entering the Japanese market. The "Alpha" here is the specific focus on Extensive-Stage Small Cell Lung Cancer (ES-SCLC)a niche where Serplulimab was the world's first PD-1 to win a 1L approval giving it a clinical edge over established Western incumbents. Eisai's local dominance in oncology makes them the perfect partner to navigate the NMPA-to-PMDA bridging process. With a Japanese filing expected in FY2026"
X Link 2026-02-08T02:15Z [---] followers, [--] engagements
"JUST IN: Stem cell biotech PrimeGen US is skipping the traditional IPO queue announcing a $1.5B SPAC merger with DT Cloud Star. The "Alpha": PrimeGen is fetching a unicorn valuation despite being pre-clinical. Wall Street is betting on their proprietary "Triple-Activated" Mesenchymal Stem Cell (MSC) platform which claims to solve the potency and scalability issues that have historically derailed stem cell therapies in liver disease. The company just concluded a Pre-IND meeting with the FDA (Dec 2025) for Acute Alcoholic Hepatitis. If they secure IND clearance they move from a "shell-deal""
X Link 2026-02-08T05:00Z [---] followers, [--] engagements
"$LLYs Tirzepatide is the new "World King" but its Chinese challenger just posted 20% weight loss data. While Eli Lilly ($36.5B in [----] sales) and Novo Nordisk ($36.1B) battle for the global crown Innovent Biologics is quietly preparing to disrupt the duopoly. New data from their Phase [--] GLORY-2 trial shows Mazdutide (GLP-1/GCG) achieving 20.1% mean weight losseffectively matching Tirzepatides gold standard. Crucially Mazdutides dual-mechanism (Glucagon + GLP-1) also drove a 71.9% reduction in liver fat potentially offering a superior metabolic profile for MASH and moderate-to-severe obesity."
X Link 2026-02-08T11:00Z [---] followers, [---] engagements
"JUST IN: Chinese NK-cell pioneer Imbue Bio just closed a nearly $30M Series B led by AI-specialist Deep Science. The "Alpha": Imbue Bio is the first in China to secure a "Chemo-free" CAR-raNK IND for solid tumors (IBR854). While Western NK plays like Fate Therapeutics and Nkarta have faced high volatility Imbues non-viral non-genetically modified ACC-NK platform is specifically designed to slash manufacturing costs and timelinesthe two biggest hurdles for off-the-shelf cell therapy. The integration of Deep Sciences AI agents into Imbue's R&D suggests a push to accelerate clinical readouts for"
X Link 2026-02-08T15:30Z [---] followers, [--] engagements
"JUST IN: Eli Lilly has officially terminated its AAV9 gene therapy program LY3884963 originally the crown jewel of its $1.04B Prevail Therapeutics acquisition. This isn't just a pipeline trimits a brutal reality check for the "Gene Replacement" strategy in CNS. Despite achieving the biological goal of delivering the GRN gene to the brain Lilly cited a "lack of compelling efficacy" in patients with Frontotemporal Dementia (FTD-GRN). The 10-year study (slated to end in 2031) was cut short because simply "getting the gene in" didn't translate to clinical improvement. This marks a significant"
X Link 2026-02-08T22:15Z [---] followers, [--] engagements
"Not sure if this fits the cancer breakthrough framing. Whats happening here is photothermal therapy not magic selectivity. SnOx nanoflakes absorb [---] nm light and convert it into heat with very high efficiency. The reported [----] C window matters because it sits right at the edge where protein misfolding and stress pathways tip cancer cells into apoptosis while many healthy cells can still recover. That apparent selectivity is not because the nanoflakes know what a cancer cell is. Its because cancer cells are already metabolically stressed redox-imbalanced and closer to their thermal failure"
X Link 2026-02-08T22:16Z [---] followers, [---] engagements
"The "ADC Capacity Crunch" has arrived. While Big Pharma fights for vial space Chinas WuXi XDC just executed a "Checkmate" move. Everyone is watching the 20+ approved ADCs hit the market. But the real bottleneck isn't the scienceit's the factory. ADC manufacturing is so complex (70% outsource rate) that global leaders Lonza and Samsung are effectively "sold out" through [----]. This capacity gap is the new "Alpha." WuXi XDC just shattered the timeline by acquiring MabPlex at a 99% premium. They didnt buy a pipeline; they bought time. While Western giants wait for new concrete to dry in [----] WuXi"
X Link 2026-02-09T02:15Z [---] followers, [--] engagements
"BREAKING: Henlius ($2696.HK) just inked a massive $388M deal with Eisai ($ESAIY) to bring its PD-1 Hancezhuang (serplulimab) to the Japanese market. This marks a significant strategic pivot. While the West is saturated with PD-1s Henlius is aggressively capturing the Asian and Emerging Market "Alpha." With a $75M upfront payment and double-digit royalties this deal validates Henliuss clinical data in SCLC (Small Cell Lung Cancer)a niche where they aim to outperform Mercks Keytruda ($MRK) on specific regional efficacy. Application filing in Japan is expected by [----]. This isn't just another"
X Link 2026-02-09T05:00Z [---] followers, [--] engagements
"JUST IN: Mercks ($MRK) Keytruda just secured its 20th NMPA approval in China marking a first-in-nation win for 1L advanced/recurrent Endometrial Cancer (EC). The NMPA gave the nod specifically for dMMR patients based on the KEYNOTE-868 trial. The data is a masterclass in immunotherapy precision: 70% reduction in risk of progression or death (HR 0.30) Median PFS: Not Reached (vs [---] months for chemo alone) Why this matters for the $XBI / $IBB landscape: While local players like Innovent ($01801.HK) and Akeso ($09926.HK) dominate broader PD-1 volumes in China Merck is successfully defending its"
X Link 2026-02-09T11:00Z [---] followers, [--] engagements
"JUST IN: Bayers ($BAYRY) Asundexian just resurrected the Factor XIa class with a massive Phase [--] win at the [----] International Stroke Conference. After a devastating failure in Atrial Fibrillation (AF) in late [----] the OCEANIC-STROKE trial has delivered the "Alpha" Bayer desperately needed: 26% reduction in recurrent ischemic stroke (csHR [----] p 0.0001) ZERO increase in ISTH major bleeding vs. placebo Consistent efficacy across all stroke subtypes (Large-artery Small-vessel etc.) This is a critical de-risking event for the entire FXIa sector. Wall Street had written off this mechanism after"
X Link 2026-02-09T15:30Z [---] followers, [--] engagements
"The "Big Pharma Restructuring" wave is hitting the titans. Genentech (Roche Group) disclosed at least [---] layoffs in [----] across its South San Francisco HQ and global units following three aggressive rounds of cuts. But don't mistake this for a retreat. This is a cold calculated pivot to "Consumer-Biotech" and AI. While cutting legacy IT and Inclusion teams Genentech is: Doubling its North Carolina manufacturing investment to $2.0B. Accelerating production for its next-gen obesity portfolio (CT-388). Aggressively hiring in AI automation and digital drug discovery. Roches ($RHHBY) 2025"
X Link 2026-02-09T19:00Z [---] followers, [--] engagements
"Exosome therapy is moving from "concept" to "commercialization" and the bottleneck isn't the scienceit's the purification. Shenzhen-based Wayen Biotech () just closed a $14M Series A+ led by Legend Capital. Their "EXODUS" platform uses a global-first acoustic nanofiltration tech that bypasses the damage caused by traditional ultracentrifugation. Why this is the "Alpha" for the pick-and-shovel play: Efficiency: Their new M-600 system handles multiple channels with AI-optimized parameters. Validation: Already installed at 300+ sites including Harvard MD Anderson and the lab of Nobel Laureate"
X Link 2026-02-09T22:15Z [---] followers, [--] engagements
"A "Patent Cliff" by design BridgeBio ($BBIO) shares cratered 15% after Pfizer ($PFE) strategically withdrew a key European patent (EP3191461B1) for its $5.5B blockbuster Vyndaqel (Tafamidis). While Pfizer claims the move was to avoid a "novelty" challenge at the EPO the secondary fallout hit BridgeBio. The logic: Early loss of Tafamidis crystalline patents could accelerate generic entry to [----] potentially crushing the pricing power and "Best-in-Class" premium for BridgeBios rival drug Attruby (Acoramidis). Why the sell-off may be overdone: Baseline assumptions for $BBIO already factored in"
X Link 2026-02-10T02:15Z [---] followers, [--] engagements
"The first-ever TIL therapy for solid tumors is proving that "earlier is better" in the real world. Iovance ($IOVA) just dropped retrospective data for Amtagvi (lifileucel) that crushes its own registrational trial numbers. In a cohort of [--] heavily pre-treated melanoma patients the Real-World Objective Response Rate (ORR) hit 44%significantly higher than the 31% that secured its FDA approval. The Investment Alpha: Early Intervention: ORR jumped to 52% for patients with [--] prior lines of therapy vs. just 33% for those in 3rd line+. DCR: 73% Disease Control Rate in a population where 30% had"
X Link 2026-02-10T05:00Z [---] followers, [--] engagements
"The "In-Vivo CAR-T" arms race just found its next technological disruptor. While Wall Street watches AbbVie ($ABBV) and Eli Lilly ($LLY) drop billions on LNP acquisitions Chinas Shutong Medical is emerging with a "hybrid" platform: LvNP (Lentivirus-like Nanoparticles). The industry is currently stuck in an "Impossible Triangle": Viral Vectors: High efficiency but high genomic risk. LNPs: High safety but low T-cell efficiency (15%). LvNP (The Disruptor): Combines viral-grade delivery efficiency with the safety of non-integrating nanoparticles. Shutong's data shows 8-12x higher payload loading"
X Link 2026-02-10T22:19Z [---] followers, [--] engagements
"BREAKING: Eli Lilly ($LLY) just made a massive $2.4B move into the "In-Vivo CAR-T" race acquiring Orna Therapeutics. This isn't just another biotech dealit's a direct shot at the future of Autoimmune treatment. Lilly is betting on Circular RNA (oRNA) to solve the biggest problem in cell therapy: Accessibility. Unlike traditional CAR-T which requires weeks of lab manufacturing Orna's platform programs T-cells directly inside the patient's body using LNPs. Key Alpha: Lead asset ORN-252 is "clinical trial-ready" for autoimmune diseases. Eliminates the need for "toxic" lymphodepletion (chemo)"
X Link 2026-02-11T02:15Z [---] followers, [--] engagements
"Merck ($MRK) is officially pivoting to its "Post-Keytruda" era targeting $70B+ in annual revenue by the mid-2030s to offset the massive [----] patent cliff. While [----] results were marred by a 35% drop in Gardasil sales (China demand cratered) the real story is the "Diversified Alpha" Merck is building to replace its $31.6B engine: Cardiometabolic Dominance: Winrevair ($1.4B in 2025) is now the PAH gold standard. Enlicitide (Oral PCSK9) just crushed Phase [--] trialsexpect a [----] FDA filing to disrupt the $AMGN/$NVO injectable market. The Defense Play: Keytruda Qlex (Subcutaneous) is the "product"
X Link 2026-02-11T05:00Z [---] followers, [--] engagements
"Kidney stones are a side issue compared to the larger question of oxalate burden renal function monitoring and G6PD deficiency screening which is mandatory before high dose IV vitamin C due to hemolysis risk. Pharmacologic ascorbate is not new. Groups at institutions like the University of Iowa have been running mechanistic and early phase trials for over a decade. The pattern is consistent: safety is generally acceptable there is a biologically plausible mechanism and there are signals in combination with chemo or radiation. What we still lack are large well powered phase III trials that"
X Link 2026-02-11T21:16Z [---] followers, [---] engagements
"Novartis CEO Vas Narasimhan just saw a 30% pay bump to $25M as $NVS crushes [----] earnings. While Big Pharma celebrates the real Alpha is hidden in the "DrugTimes" briefing attached to this report: Global VCs are now aggressively hunting for Chinese oral TL1A inhibitors to rival the injectable blockbusters from Roche and Sanofi. The data gap is closing. While $NVS rides the success of Scemblix (+85%) and Fabhalta (+287%) Western capital is pivoting to "NewCo" structures for Chinese oral assets to hedge against the looming $4B patent cliff on Entresto. Everyone is chasing the $NVS dividend but"
X Link 2026-02-11T22:15Z [---] followers, [--] engagements
"AstraZeneca ($AZN) just reported FY2025 revenue of $58.7B (+8%) and is doubling down on China with a massive [---] Billion RMB ($15B) investment pledge through [----]. The strategy is clear: Use the massive cash flow from oncology ($25B+) to dominate the obesity market via Chinese innovation. This weeks core "Alpha" is the Phase [--] win for Elecoglipron (licensed from Eccogene) which is now advancing to Phase [--]. While the market fixates on $LLY and $NVO $AZN is quietly building an obesity "super-pipeline" by acquiring ex-China rights to assets like CSPCs $18.5B monthly injectable and Eccogenes oral"
X Link 2026-02-12T02:15Z [---] followers, [--] engagements
"The "Holy Grail" of regenerative medicineactual organ repairjust hit a commercial milestone in China. Regend Therapeutics () has closed a 350M RMB ($48M) Series C to scale the worlds first autologous lung progenitor cell therapy for COPD and IPF. While Western giants like United Therapeutics ($UTHR) focus on organ manufacturing and ex-vivo perfusion Regend is "regenerating" healthy alveoli inside the patient. Their lead asset REGEND001 has already moved beyond the lab and into the real world: Commercial Launch: Already treating patients at the Boao Lecheng Pilot Zone. Real-World Pricing:"
X Link 2026-02-12T11:00Z [---] followers, [--] engagements
"Upstream Bio ($UPB) just crashed 47% after its Phase [--] asthma data failed the "Convenience Test." While their 12-week dosing matched the efficacy of the gold standard Tezspire ($AZN/$AMGN) the ambitious 24-week (twice-yearly) arm fell short. In the high-stakes TSLP market "good enough" is a death sentence. This failure creates a massive opening for Chinese-originated assets that are currently being weaponized by Big Pharma. The real winners today GSK and its asset AIO-001 (originally from Hengrui Medicine). GSK paid $1B upfront precisely because AIO-001 is engineered for that elusive 6-month"
X Link 2026-02-12T22:15Z [---] followers, [--] engagements
"JUST IN: Sanofi ($SNY) has ousted CEO Paul Hudson after a six-year "transformation" that left investors frustrated by stalled R&D and over-reliance on Dupixent. In a power move the board poached Merck KGaA ($MRK.DE) CEO Beln Garijo to take the helm. This isn't just a leadership change; its a mandate for "increased rigor." Hudsons tenure saw a 33% returnpaling in comparison to AstraZenecas 133% and GSKs 65%. With Dupixents patent cliff looming in [----] and recent pipeline failures like amlitelimab and tolebrutinib the board is betting on Garijos reputation for clinical and operational"
X Link 2026-02-13T02:15Z [---] followers, [---] engagements
"Sanofi ($SNY) is doubling down on molecular glues. The French giant just cut a $30M strategic equity check to Shanghai-based GluBio Therapeutics to accelerate two preclinical assets GLB-005 and GLB-007 for Sickle Cell Disease (SCD). The "Alpha": Sanofi isn't just investing; they secured a Right of First Negotiation (ROFN) to license these drugs. GLB-005 and GLB-007 work by selectively degrading WIZ and ZBTB7Arepressors that keep fetal hemoglobin (HbF) turned off in adults. By "gluing" these repressors to degradation machinery GluBio can reactivate HbF potentially offering an oral"
X Link 2026-02-13T11:00Z [---] followers, [--] engagements
"This is not LSD [---]. It is part of a broader class of compounds often called psychoplastogens: molecules that promote structural plasticity particularly dendritic spine growth and synaptogenesis in the prefrontal cortex. The key biology here revolves around 5-HT2A receptor signaling. Classic psychedelics like Lysergic acid diethylamide activate 5-HT2A receptors which couple to Gq/11 proteins increase intracellular Ca and engage downstream pathways such as: mTOR BDNF/TrkB signaling ERK/MAPK cascades These pathways converge on cytoskeletal remodeling and synapse formation. The innovation"
X Link 2026-02-13T22:50Z [---] followers, [---] engagements
"NK cells are officially the next frontier in the "Off-the-Shelf" cell therapy war. Just [--] days after closing a 200M RMB Series B InnoCell () just had [--] INDs for IBR900 accepted by the CDE. While the West struggles with the high costs of autologous CAR-T InnoCell is cornering the allogeneic (donor-derived) market in China with a massive 30% share of all domestic NK clinical licenses. The data gap is closing: InnoCells IBR900 (Phase 1) is showing a 0% rate of severe CRS or neurotoxicitythe primary "safety tax" paid by current B-cell therapies like $GILDs Yescarta or $BMYs Breyanzi. Everyone is"
X Link 2026-02-14T02:15Z [---] followers, [--] engagements
"BREAKING: Lyell Immunopharma ($LYEL) has dosed the first patient in a world-first Phase [--] "Head-to-Head" CAR-T trial (PiNACLEH2H). This is a direct assault on the standard-of-care. Lyell is pitting its CD19/CD20 dual-targeting therapy ronde-cel against $GILDs Yescarta and $BMYs Breyanzi. Why this is "Alpha": Antigen Escape Solved: While 20%+ of patients relapse on current CAR-Ts due to CD19 loss ronde-cel uses an "OR-gate" logic to hit CD20 as a backup. Superior Data: Early 93% Objective Response Rate (ORR) and 76% Complete Response (CR) in 3L+ settings. Outpatient Safety: Only 4% severe"
X Link 2026-02-14T08:00Z [---] followers, [--] engagements
"CAR-T therapy is evolving from a cancer "moonshot" into an antiviral tactical strike. While the West focused on $GILD and $BMY for oncology China is quietly leading the pivot toward functional cures for HIV and Chronic HBV. The mechanism shift is genius: Chronic viruses like HBV and HIV cause "immune exhaustion" making native T cells useless. CAR-T bypasses this by engineering T cells to recognize viral envelope proteins (like HBsAg or gp120) without needing MHC-I presentationeffectively stripping the virus of its favorite invisibility cloak. The "China Edge" here is solving the Antigen"
X Link 2026-02-15T08:00Z [---] followers, [--] engagements
"Takeda ($TAK) is doubling down on the AI revolution signing a $1.7B deal with Iambic Therapeutics to overhaul its small-molecule discovery engine. This isn't just about speedit's about "undruggable" targets. Takeda is gaining access to NeuralPLexer an AI model that predicts how drugs bind to proteins at the atomic level potentially cutting discovery timelines from [--] years to under [--]. Key Insights: Targets: High-priority programs in Oncology GI and Inflammation. Efficiency: Weekly "design-make-test" cycles using automated wet-labs. Sector Momentum: This follows Qilu Pharmaceuticals $120M AI"
X Link 2026-02-11T08:00Z [---] followers, [--] engagements
"BREAKING: The FDA has officially signaled a "green light" for the first autoimmune CAR-T (miv-cel) to skip Phase [--] and head straight for a 1H [----] BLA submission. In a landmark stance published in the Annals of Internal Medicine FDA officials (including CBER Director Vinay Prasad) confirmed they are open to "Accelerated Approval" based on Phase [--] data for high-unmet-need conditions like Stiff Person Syndrome (SPS). This is the "Alpha" trigger for the sector: The FDA is prioritizing efficacy over long-term data for the initial approval acknowledging that the "immune reset" mechanism in"
X Link 2026-02-11T21:03Z [---] followers, [--] engagements
"Move over IL-4/IL-13. The "Upstream" war in Atopic Dermatitis (AD) has officially begun. Evommune ($EVMN) stock skyrocketed 70% after EVO301an IL-18 fusion proteindelivered Phase 2a data that rivals the efficacy of Sanofis $77B blockbuster Dupixent ($SNY). The Alpha: While Dupixent targets downstream Th2 cytokines EVO301 hits IL-18 the "Master Switch" that controls Th1 Th2 and Th17 pathways. This allows it to treat the "difficult-to-treat" patients who fail current biologics. $SNY and $REGN should be watching their rear-view mirror. $EVMN just proved that neutralizing IL-18 isn't just a"
X Link 2026-02-12T05:00Z [---] followers, [---] engagements
"The "Immunology Renaissance" is picking up speed. Nektar Therapeutics ($NKTR) stock surged 51% today after its Treg-selective IL-2 Rezpegaldesleukin (REZPEG) delivered massive Phase 2b maintenance data. The Alpha: Not only did REZPEG maintain disease control for [--] weeks but responses actually deepened over time. Patients reaching EASI-100 (complete skin clearance) jumped from 6% to 30% during the maintenance phase. This suggests a "disease-modifying" effect that current blockbusters like Dupixent ($SNY) haven't demonstrated. Even more disruptive The dosing. While Dupixent requires bi-weekly"
X Link 2026-02-12T08:00Z [---] followers, [--] engagements
"The Chinese ADC engine is hitting overdrive. Three domestic players just secured NMPA clinical trial approvals targeting massive indications with high-alpha mechanisms. [--]. Lepu Biopharma ($2157.HK) - MRG006A (GPC3-ADC) This is a potential First-in-Class for Hepatocellular Carcinoma (HCC). The Data: Phase [--] results showed "significant tumor shrinkage" in [--] patients. The Edge: It utilizes the Hi-TOPi platform to solve the GPC3 selectivity problem. With FDA Orphan Drug Designation already in hand Lepu is eyeing a global Phase [--] in [----]. [--]. CSPC Megalith ($1093.HK / $300765.SZ) - SYS6023"
X Link 2026-02-12T20:34Z [---] followers, [--] engagements
"JUST IN: Eli Lillys ($LLY) Tirzepatide (Mounjaro) has just secured NMPA approval in China for T2DM monotherapy. This is a strategic "Game Over" move for the early-stage diabetes market expanding its label to cover the entire patient journey from first-line treatment to advanced combination therapy. The "Alpha": This approval based on the SURPASS-CN-MONO study effectively weaponizes $LLY against the massive wave of upcoming Chinese GLP-1 biosimilars. While local players are fighting for weight-loss market share Lilly is locking in the 148M Chinese diabetic population as the "standard of care""
X Link 2026-02-13T05:00Z [---] followers, [--] engagements
"A massive $4.4 Billion "Alpha" just dropped in the MASH space. Madrigal Pharmaceuticals ($MDGL) has signed a global licensing deal with Suzhou Ribo Life Science ($06938.HK) for six preclinical siRNA programs. This is a "Defensive Consolidation" move. Madrigal currently owns the only FDA-approved MASH drug Rezdiffra. But with Novo Nordisk ($NVO) and Eli Lilly ($LLY) looming Madrigal is pivoting to combination therapy. By leveraging Ribos GalSTAR platform Madrigal aims to pair their oral drug with siRNA gene silencers to target the genetic drivers of liver diseasecreating a "moat" that GLP-1s"
X Link 2026-02-13T08:00Z [---] followers, [--] engagements
"The "Drug Delivery" Holy Grail just got a manufacturing upgrade. Shanghai-based Scipu and ATMP specialist Billionet () have signed a strategic pact to scale engineered exosomes. Exosomes are the "natural nanoparticles" of the bodylow immunogenicity high tissue penetration and the ability to cross the blood-brain barrier (BBB). While the science is proven the industry has been stuck in the "Manufacturing Valley of Death": non-standardized processes and impossible-to-scale yields. The Alpha: This partnership targets the single biggest bottleneck in advanced therapiesCMC (Chemistry Manufacturing"
X Link 2026-02-13T15:30Z [---] followers, [--] engagements
"The "Valley of Death" in Cell & Gene Therapy (CGT) is wider than investors realize. New data from Academician Cheng Tao reveals a staggering drop-off: while there are [---] Phase [--] trials for Cell-Based Immuno-Oncology (CBIO) globally only [--] have made it to Phase [--]. The industry is hitting a massive clinical bottleneck. Here is the Alpha on where the puck is going. The Science: Most CGT success has been confined to "Liquid Tumors" (Blood cancers). The mechanism involves ex-vivo engineering of T-cells. But the "Solid Tumor" wall is realthe immunosuppressive microenvironment of solid masses is"
X Link 2026-02-13T22:45Z [---] followers, [--] engagements
"BREAKING: Novartis CEO Vas Narasimhans [----] compensation surged 30% to 24.9M CHF ($28.3M USD) driven by a massive 188% payout on long-term performance targets. This "pay-for-performance" milestone comes as Novartis hits its 40% core margin goal two years ahead of schedule. However the "King of Pharma" now faces a $4 billion revenue hole. The Alpha: Despite record financials ($54.5B sales in 2025) Novartis has officially entered the "largest patent cliff in company history." The Hit: U.S. generics for Entresto Promacta and Tasigna are gutting the old guard. Entresto sales already plunged 45%"
X Link 2026-02-14T11:00Z [---] followers, [--] engagements
"iPSC-based regenerative medicine is no longer "science fiction"it is a capital-intensive race for the $30B Parkinsons market. Yuesai Biotech () just closed its 140M RMB ($20M) Series A+ round bringing its total war chest to 300M RMB. Their lead asset UX-DA001 is the first iPSC-derived autologous therapy to receive dual IND clearance from both the NMPA and FDA positioning them as the primary global challenger to Bayers BlueRock. The real Alpha lies in the "Autologous vs. Allogeneic" safety profile: While Western leaders like BlueRock ($BAYRY) often require [--] months of immunosuppressants for"
X Link 2026-02-14T15:30Z [---] followers, [--] engagements
"BREAKING: Immunofoco () has officially filed for its Hong Kong IPO aiming to solve the "Solid Tumor Wall" that has defeated Western CAR-T giants. With a fresh post-money valuation of $290M (2.07B RMB) following its Series C the company is positioning its lead asset IMC002 as the global front-runner for gastrointestinal cancers. The Alpha: The Efficacy Lead: IMC002 (targeting CLDN18.2) just posted a massive 66.7% Objective Response Rate (ORR) at ASCO GI [----]. This includes a durable Complete Response (CR) lasting over a year in late-line gastric cancer patients. The "In Vivo" Pivot: Beyond"
X Link 2026-02-14T19:00Z [---] followers, [--] engagements
"BREAKING: FDA issues CRL to Disc Medicines Bitopertin for Erythropoietic Protoporphyria (EPP) marking the first major failure of the ultra-fast CNPV (Commissioners National Priority Voucher) pathway. Despite Bitopertin achieving its primary endpoint in Phase [--] trials the FDA rejected the use of PPIX levels as a surrogate biomarker questioning if a 40% reduction in protoporphyrin actually translates to real-world sunlight tolerance for patients. This rejection signals a massive regulatory shift under the Makary-led FDA: the "Super-Priority" speed of CNPV does NOT lower the bar for clinical"
X Link 2026-02-15T19:00Z [---] followers, [--] engagements
"The "Godfather" of Chinese CAR-T is backand he claims to have solved the durability problem for Off-the-Shelf therapies. Dr. Fan Xiaohu the scientific founder who built Legend Biotech ($LEGN) into a $10B powerhouse with Carvykti has emerged with data from his new venture: Wondercel Therapeutics. The Holy Grail: Universal (Allogeneic) CAR-T. Current Problem: Allogeneic therapies (using donor cells) are cheap but usually fail on durability (they stop working too fast). Fans Update: Lymphoma: Wondercel's Universal CAR-T is showing efficacy comparable to Autologous (custom) strains with patients"
X Link 2026-01-28T02:15Z [---] followers, [---] engagements
"The "China Edge" in oncology and immunology is no longer just about lower costsit's about superior engineering. The latest NMPA filings show Chinese biotechs tackling the "unmet needs" of Western blockbusters. Hengruis SHR-A2102 (Nectin-4 ADC) is proving that Topo-I payloads can rescue patients who fail Pfizers Padcev. Data shows a 38% response rate in ADC-pretreated populations. Meanwhile Akeso ($9926.HK) is moving AK139 into P2. By targeting both IL-4R and ST2 they are going after the "Refractory Asthma" market that Regenerons Dupixent cant fully capture. Finally the trispecific era is"
X Link 2026-02-16T02:15Z [---] followers, [--] engagements
"The "Ex Vivo" CAR-T era is hitting a wall. Manufacturing complexity and the $500k+ price tag are scaling bottlenecks that even big pharma can't ignore. The next frontier In Vivo CAR-T. Chinas NMPA (CDE) just released a definitive framework for "In Situ" engineering. Instead of taking cells out we send the "factory" into the patient using Viral Vectors or LNPs. Why this is the ultimate Alpha play: No Lymphodepletion: Eliminates toxic pre-conditioning chemotherapy. Zero Wait Time: Removes the 3-4 week "vein-to-vein" manufacturing lag. Scalability: Turns cell therapy into an "off-the-shelf""
X Link 2026-02-17T02:15Z [---] followers, [--] engagements
"The era of "Cell-Free" Regenerative Medicine has arrived. While the market obsesses over CAR-T the real Alpha is in Stem Cell Exosomes. New 5-year data confirms that Chinese researchers have moved from lab curiosity to clinical dominance particularly in hard-to-reach indications like the Central Nervous System (CNS) and Respiratory systems. The Insight: Stem cell exosomes are the "FedEx" of the body. They carry the regenerative cargo of a stem cell (miRNA proteins) but without the "cell" itself. This means 0% risk of tumorigenicity easier storage and no immune rejection. The China Edge: CNS"
X Link 2026-02-14T05:00Z [---] followers, [--] engagements
"AstraZeneca ($AZN) just fired the starting gun on the worlds first Phase [--] trial for a "Fast CAR-T" (AZD0120). While the market obsesses over "In Vivo" (in-body) engineering AZN is proving that "Fast" (next-day manufacturing) is the bridge to mass-market cell therapy. By bypassing the 3-week expansion phase they aren't just cutting coststhey are delivering "fitter" T-cells with a 100% ORR in early trials. Everyone is watching Novartis ($NVS) and their T-Charge platform. But AstraZeneca ($AZN) just moved into the lead with the DURGA-4 global Phase [--] effectively leapfrogging the competition. If"
X Link 2026-02-17T05:00Z [---] followers, [--] engagements
"JUST IN: AstraZeneca ($AZN) announces a massive $15 billion (100B RMB) investment in China through [----] marking the largest commitment by a Western pharma giant to the region. Announced during the UK PM's visit to Beijing this isn't just about manufacturingits a strategic bet on China as the global hub for "Next-Gen" modalities: Cell Therapy: Integrating the $1B Gracell acquisition and recent $630M AbelZeta deal ($AZD5851/C-CAR031). Radioconjugates (RDC): Rapidly expanding local supply chains for the newest oncology frontier. Local Ecosystem: Deepening R&D ties with Cambridge Oxford and"
X Link 2026-01-30T08:00Z [---] followers, [--] engagements
"Eli Lilly ($LLY) just dropped another $1.1B+ into its hearing loss "monopoly" strategy this time partnering with German biotech Seamless Therapeutics for their programmable recombinase platform. While the market is fixated on GLP-1s $LLY has quietly built a vertical dominant force in genetic deafness: 2022: Bought Akouos ($610M) AAV gene therapy for OTOF mutations. 2025: Partnered with Rznomics ($1.3B) RNA-editing for sensorineural loss. 2026: Seamless Deal ($1.12B) Programmable recombinases for large-scale DNA insertion. The "Alpha" here: Seamless technology is a massive upgrade over CRISPR."
X Link 2026-01-30T11:00Z [---] followers, [--] engagements
"Lisata Therapeutics ($LSTA) and Qilu Pharmaceutical have mutually terminated their [----] license agreement for Certepetide (formerly CEND-1). All Greater China rights now revert to Lisata but the real story is the arbitrage-play acquisition behind the scenes. This move was effectively forced by Kuva Labs a private cancer imaging specialist that entered a binding agreement to acquire Lisata on Jan [--] [----]. To secure a massive 180% total premium Lisata shareholders are incentivized by two Contingent Value Rights (CVRs): CVR [--] ($1.00/share): Triggered by the reversion of China rights (Achieved)."
X Link 2026-01-30T15:30Z [---] followers, [--] engagements
"The NMPA (China) just overhauled its "Drug Administration Law Implementation Regulations" effective May [--] [----]. This isn't just a compliance updateits a massive structural tailwind for innovative Western biotechs entering China and Chinese biotechs scaling globally. Here is the "Alpha" you need to know: Market Exclusivity is finally codified: Orphan Drugs: Up to [--] years of market exclusivity (matching the US FDA standard). Pediatric Drugs: Up to [--] years of exclusivity. Data Protection: [--] years of protection for undisclosed clinical data. This is a huge win for MNCs like $MRK and $LLY to"
X Link 2026-01-30T19:00Z [---] followers, [--] engagements
"Olympus ($OCPNY) has officially appointed Rosa Chen () as the first-ever local President for its China operations effective March [--] [----]. This marks a massive pivot in the Japanese giants governance structure and signals an aggressive "Localized Globalism" strategy. Why this is a market-moving hire: Strategic Shift: Rosa Chen comes directly from Danaher ($DHR) where she led the Diagnostics DBS platform. Her deep expertise in operational excellence and diagnostics is the perfect fit for Olympus evolution beyond just GI scopes into integrated surgical solutions. New Leadership Architecture:"
X Link 2026-01-31T02:15Z [---] followers, [--] engagements
"Everyone is watching Eli Lillys ($LLY) Orforglipron. But Hengrui Pharma ($600276.SH) just moved its oral small-molecule GLP-1 HRS-7535 into a Phase [--] trial for a massive new "Alpha" indication: Hypertension combined with obesity. This moves the needle beyond just weight loss and into comprehensive cardiometabolic management. Create a comparison table. Left: $LLY Orforglipron (P2 data: 14.7% weight loss at [--] weeks). Right: $600276.SH HRS-7535 (P2 data: 9.36% weight loss at only [--] weeks with 41.7% of patients losing 10%). Note: HRS-7535 is now clinical-track for Hypertension and Diabetic"
X Link 2026-01-31T05:00Z [---] followers, [--] engagements
"Forget the "Big Pharma only" narrative. Three Tsinghua PhDs just turned a decade of academic research into a $140M commercial catalyst. Beijing Immunotech () just secured a massive distribution deal with Huadong Medicine ($000963.SZ) for their lead CAR-T IM19. With their NDA already accepted this is no longer a "science project"its a [----] revenue story. Why the market is underestimating this: Efficacy: 71% ORR in Lymphoma (Beating established incumbents). Safety: Engineered for lower neurotoxicity allowing for broader clinical use. Scale: Huadongs massive sales force removes the"
X Link 2026-01-31T22:15Z [---] followers, [--] engagements
"JUST IN: Eli Lilly ($LLY) is weaponizing its obesity cash flow to monopolize the "Cure for Deafness" market. Lilly just signed an $1.12B strategic deal with Germanys Seamless Therapeutics to utilize their "programmable recombinase" platform. While standard CRISPR struggles with large-scale gene insertions and off-target "messiness" recombinases allow for surgical site-specific DNA replacementthe holy grail for complex genetic mutations behind hearing loss. Why this is a major Alpha move: Zero Competition: There are currently zero approved drugs for hearing restoration. De-risked Strategy:"
X Link 2026-02-01T02:15Z [---] followers, [---] engagements
"The "China Biotech Winter" is officially over for the top 10%. New data reveals that 84B RMB ($11.7B) flowed into Chinese healthcare in 2025a 14% YoY jump. But the money isn't chasing "me-too" PD-1s anymore. The elite VCs (Qiming BioTrack Lilly Asia) have shifted to three high-conviction "Value" pillars: Extra-Hepatic RNAi: Starna Therapeutics () just closed a $110M round with strategic backing from Eli Lilly ($LLY). While $ALNY and $ARWR dominate liver-based RNAi the smart money is betting on China to crack the code for delivery to the heart brain and kidneys. Next-Gen TILs: Grit Bio ()"
X Link 2026-02-01T05:00Z [---] followers, [--] engagements
"Hengrui Pharmaceuticals ($600276.SH) is officially graduating from "Chinas Generic King" to a Global Top [--] Pharma powerhouse. At a $61B market cap it has already unseated Takeda and Bayer. The market is underestimating the "Hengrui Shift." While most Chinese biotechs focus on simple licensing Hengrui is executing a sophisticated three-pronged global offensive: The "NewCo" Masterclass: Instead of a standard out-license they spun off their GLP-1 portfolio into Kailera Therapeutics (formerly Hercules) with Bain Capital. Hengrui keeps 19.9% equity + milestones. This "de-risked" their metabolic"
X Link 2026-02-01T19:00Z [---] followers, [--] engagements
"China just officially flipped the script on Western Pharma. In [----] Chinese out-licensing (BD) deals hit a staggering $135.7B accounting for 49% of total global deal value. For the first time in history China has surpassed the US as the primary source of pharmaceutical innovation exports. We are entering the "BD [---] Era." The days of Western firms buying "cheap Chinese assets" are over. Today Big Pharma is paying a massive "certainty premium" for late-stage de-risked data. The three shifts you need to track for your portfolio: Cash is King: Upfront payments nearly doubled in [----] to $7B. Look"
X Link 2026-02-01T22:15Z [---] followers, [--] engagements
"JUST IN: NeuShen Pharma () has closed a multi-million dollar Series A+ round led by Lilly Asia Ventures (LAV). This capital infusion is earmarked to accelerate their Central Nervous System (CNS) pipeline into clinical trials. The "Alpha" here is the lead investor. Lilly Asia Ventures leading a CNS round in [----] is a massive signalit's effectively the "Lilly Seal of Approval" on NeuShen's proprietary platforms for neuropsychiatric and neurodegenerative disorders. While most of the sector is chasing overcrowded ADC and GLP-1 targets NeuShen is attacking the high-barrier CNS market where Eli"
X Link 2026-02-02T02:15Z [---] followers, [--] engagements
"Moderna ($MRNA) just proved that mRNA cancer vaccines aren't a fluke5-year data shows a 49% reduction in recurrence/death when paired with Keytruda. But while Wall Street chases $MRNA a specialized "China Alpha" is emerging in neoantigen tech that could leapfrog Western delivery methods. The science is complex but the math is simple: Take a patients unique tumor mutations use AI to predict which "neoantigens" will trigger the immune system and deliver that code via mRNA. It is the ultimate personalized medicine. The China Edge isn't just speed; its the "Combo Strategy." While $MRNA is"
X Link 2026-02-03T02:15Z [---] followers, [---] engagements
"Stop calling it the Keytruda "Patent Cliff." Merck ($MRK) just laid out the blueprint for a "$70B Slope" and the foundation is built on Chinese engineering. The strategy to survive [----] relies on two technical shifts: "Bio-better" delivery and "Precision" ADCs. While the market fears a revenue crater Merck is aggressively converting the patient base to QLEX (Subcutaneous Keytruda). Goal: 30-40% adoption within [--] months. Impact: Preserves the "Long Tail" of the franchise by moving patients from IV to a more convenient SC injection before the [----] biosimilar wave. The real "China Alpha" is"
X Link 2026-02-03T05:00Z [---] followers, [--] engagements
"Forget the slow million-dollar ex-vivo CAR-T process. The "Holy Grail" of autoimmune therapy just landed in two back-to-back NEJM papers and Chinese researchers are officially leading the world in "In Vivo" cellular reprogramming. The science is shifting from "Managing" to "Curing." For decades Systemic Lupus Erythematosus (SLE) and Autoimmune Hemolytic Anemia (AIHA) were lifelong sentences of steroids and immunosuppressants. China just proved we can use mRNAthe same tech in COVID vaccinesto turn a patients own $CD8+$ cells into B-cell killers inside their own body. The Insight: Traditional"
X Link 2026-02-03T22:15Z [---] followers, [--] engagements
"While the market is obsessed with the "duopoly" of Eli Lilly ($LLY) and Novo Nordisk ($NVO) Roche ($RHHBY) is quietly building an "Obesity 2.0" fortress. At JPM [----] Roche CEO just dropped a bombshell: Unlike their Big Pharma peers Roche faces zero patent cliffs through [----]. The Alpha: Roche isn't just chasing the GLP-1 trend; they are engineering a superior metabolic stack. Their dual agonist CT-388 just posted a massive 22.5% weight loss at [--] weeks (Phase 2) rivaling $LLYs Zepbound. But the real edge is the combination potential. Roche is the first to systematically pair a GLP-1/GIP"
X Link 2026-02-04T02:15Z [---] followers, [--] engagements
"JUST IN: Corxel Pharmaceuticals ($) closes a massive $287M Series D1 to challenge the oral GLP-1 duopoly of $LLY and $NVO. This is one of the largest private biotech rounds in [----] backed by a syndicate of "smart money" heavyweights including RA Capital RTW and TCG Crossover. The "Alpha": Corxel isn't just another Chinese biotechthey are pivoting into a global cardio-metabolic powerhouse. The capital is strictly earmarked for the global Ph2/3 development of CX11 a daily oral small-molecule GLP-1 RA. Unlike many domestic peers seeking local NMPA approval Corxel is running US-based trials to"
X Link 2026-02-04T05:00Z [---] followers, [---] engagements
"BREAKING: AstraZeneca ($AZN) just committed a massive $15B (100B RMB) investment in China through [----] marking the largest-ever commitment by a foreign Big Pharma in the region. CEO Pascal Soriot joined the UK Prime Minister's delegation to signal a strategic pivot toward Chinese-led innovation in Cell Therapy and Radioconjugates (RCM). Simultaneously $AZN released pivotal Phase [--] data for the AZALEA trial (Anifrolumab) in Asian/Chinese patients with Systemic Lupus Erythematosus (SLE). The results confirm high efficacy and a significant reduction in steroid usethe "Holy Grail" for SLE"
X Link 2026-02-04T08:00Z [---] followers, [--] engagements
"Pfizers $10B bet on Metsera (PF'3944) just hit a major Phase 2b milestone but the market isn't buying the hype. While PF'3944 hit 12.3% weight loss at [--] weeks with a monthly dosing pivot the data carries red flags compared to the gold standard. Despite the ultra-long-acting monthly convenience the safety profile is trailing behind Eli Lilly. Discontinuation rates due to adverse events hit 10% for PF'3944significantly higher than the 6.2% seen with Zepbound. Pfizer is doubling down with a massive Phase [--] program including a higher 9.6mg dose to chase 16%+ weight loss but for now the "Biased"
X Link 2026-02-04T22:15Z [---] followers, [--] engagements
"2025 was the year small nucleic acid drugs (Oligonucleotides) graduated from "niche biotech" to "market dominant." From Novartis $12B shopping spree to siRNA data that makes "weekly" GLP-1s look obsolete the landscape has fundamentally shifted. The Insight: We are moving beyond simple liver targeting. The new "Alpha" lies in AOCs (Antibody-Oligonucleotide Conjugates) and Bivalent siRNA. Bivalent designs use a linker to join two siRNA units doubling stability and enabling "dual-pathway" interferenceessential for tackling complex neuro and muscular diseases. The China Edge: Chinese biotechs"
X Link 2026-02-05T08:00Z [---] followers, [--] engagements
"2026 is officially the year of the "Regulatory Breakthrough." Ultragenyx has just resubmitted its BLA for UX111 backed by an unprecedented [---] years of clinical data. This isn't just a win for MPS IIIA patients; it's a signal that the FDA is clearing the CMC logjam for AAV therapies. We are entering a massive BLA sprint this year with 7+ potential first-in-class launches: Ultragenyx ($RARE): UX111 (First MPS IIIA Gene Therapy) - PDUFA likely Q3 [----]. GSK ($GSK): Bepirovirsen (First functional cure for Hep B via siRNA) - Filing Q1 [----]. Kyverna ($KYTX): KYV-101 (First CAR-T for Stiff-Person"
X Link 2026-02-05T19:00Z [---] followers, [--] engagements
"Roche is doubling down on its RNAi comeback. Today the Swiss giant announced a $1.7 billion global licensing deal with SanegeneBio to acquire a novel RNA interference therapy. This is a massive back-to-back win for SanegeneBio. In late [----] Eli Lilly ($LLY) committed $1.2 billion to the same platform for cardiovascular metabolic targets. Now Roche is paying $200M upfront to secure its own slice of Sanegene's "twice-a-year" siRNA technology. The deal highlights a major industry shift: the "Big Pharma" arms race for metabolic dominance is moving beyond GLP-1 peptides and toward siRNA therapies"
X Link 2026-02-05T22:15Z [---] followers, [--] engagements
"JUST IN: Novo Nordisk taps ex-Merck veteran Hong Zhou as EVP of Strategy Execution to defend its China fortress. This is a high-stakes hire ahead of the looming Ozempic patent cliff. The Alpha: Semaglutide China patent expires March [----]. Domestic revenue is only 6% of total sales despite massive demand. Growth guidance is already cooling (5-13% dip expected for 2026). By bringing in a specialist who navigated market access for Roche and Merck $NVO is signaling a pivot from "Global Supply" to "Local Trench Warfare" against Chinese biosimilar players and Innovent. $NVO $LLY $01801.HK $HXP $XBI"
X Link 2026-02-06T02:15Z [---] followers, [--] engagements
"BREAKING: Eli Lilly ($LLY) has terminated LY3884963 a key gene therapy for Frontotemporal Dementia (FTD-GRN) acquired in its $1B buyout of Prevail Therapeutics. The Alpha: Lilly is ruthlessly pruning its pipeline to focus on its high-margin GLP-1/GIP juggernauts. While the termination was due to efficacynot safetyit highlights the immense technical hurdles still facing the AAV gene therapy sector for CNS diseases. This exit leaves a massive opening in the FTD market for smaller focused innovators. Lilly also axed two other programs (Rheumatoid Arthritis and Prostate Cancer) to shift resources"
X Link 2026-02-06T11:00Z [---] followers, [--] engagements
"A few critical clarifications are needed here otherwise this gets misread very quickly. In vitro in vivo. An 84% reduction in amyloid microclots in a controlled test tube environment tells us something about biochemical capability not clinical efficacy. Plasma flow dynamics endothelial interactions immune regulation dosing kinetics and off-target fibrinolysis are not represented in these assays. Amyloid microclots are not a settled pathology. The definition detection methods and clinical relevance of these structures are still actively debated. Some studies rely on fluorescent staining"
X Link 2026-02-06T21:09Z [---] followers, [----] engagements
"Parkinson's is moving from "symptom management" to "structural repair." Bayer ($BAYRY) has officially accelerated its bemdaneprocel (BRT-DA01) stem cell therapy into a pivotal Phase [--] skipping P2 with a target filing date of [----]. This is the "Holy Grail" of neurology. The data validation is global. In China Shanghai Ruijin Hospital just reported that their first iPSC-transplanted patient saw dopamine uptake levels jump by 44.7%proving these "new" neurons aren't just surviving; they are integrating and firing. Wall Street has ignored the regenerative neuro space due to past failures but the"
X Link 2026-02-07T02:15Z [---] followers, [---] engagements
"The GLP-1 "Infinite Growth" narrative just hit a wall. Novo Nordisk ($NVO) shares have cratered 26% in [--] hours after the company issued a shock [----] guidance: Adjusted sales growth could drop by as much as 13%. This isn't just a "miss"its a structural collapse of the obesity drug premium. Three factors are crushing the stock: The "TrumpRx" & MFN pricing agreements are gutting U.S. net prices. Chinas semaglutide patent expires in [----] opening the gates for a generic flood. Eli Lillys ($LLY) oral orforglipron is tracking for a Q2 [----] FDA approval threatening to leapfrog Novos pill launch."
X Link 2026-02-07T08:00Z [---] followers, [--] engagements
"THE KRAS KILLER Astellas ($ALPMY) just dropped a data bomb on the Pancreatic Cancer market. While Amgen ($AMGN) and Mirati fought over lung cancer Astellas quietly built a best-in-class pipeline for the "undruggable" targets. The Data (JPM Reveal): [--]. Breaking the Pancreatic Curse (ASP3082): Standard KRAS inhibitors struggle in pancreatic cancer. Astellas' Protein Degrader (ASP3082) + Chemo just posted a stunned 58.3% ORR and 83.3% Disease Control Rate. Mechanism: It degrades the KRAS G12D mutant protein entirely rather than just blocking it. [--]. The Gastric Cancer Moat (ASP2138): Their"
X Link 2026-01-15T02:15Z [---] followers, [--] engagements
"CG Oncology ($CGON) has been the main trade for Bladder Cancer (NMIBC). But a new challenger just posted perfect data at SUO [----]. The New Data (High Dose Cohort): 100% Complete Response in Carcinoma In Situ (CIS). 100% Recurrence-Free Survival in Papilloma. Safety: Clean. No Dose-Limiting Toxicities. With the global BCG shortage the race for the NMIBC crown is wide open. ImmVira is already running a US Phase [--]. This is the asset that could disrupt the $CGON thesis. $CGON $MRK $JNJ $XBI $IBB https://twitter.com/i/web/status/1997570276880736542"
X Link 2025-12-07T07:34Z [---] followers, [--] engagements
"Zai Lab ($ZLAB) and Zymeworks ($ZYME) leadership just confirmed this shift. The US wants the assets not the conflict. With the XBI rebounding (+75% from April lows) the smart money is buying the "Source Code" of these pipelines. The next frontier identified"
X Link 2025-12-29T02:15Z [---] followers, [--] engagements
"BREAKING: Hillhouse Capital just dumped $785M USD (6.1B HKD) of BeiGene stock slashing their stake by nearly half (8.97% 4.89%). Simultaneously BeiGene ($BGNE) is pivoting to a "Dual President" structure. Global R&D Head Lai Wang has been promoted to President sharing power with current President/COO Xiaobin Wu. The Alpha: This is a massive "Smart Money" rotation. Hillhouse is exiting the high-growth biotech play to rotate into legacy giant Hengrui Pharma. Why BeiGene is now profitable but heavily reliant on a single asset (Brukinsa = 70% of revenue). The PD-1 (Tevimbra) rollout in the West"
X Link 2026-01-04T05:00Z [---] followers, [--] engagements
"BREAKING: Roche just cut a $100M check to Structure Therapeutics ($GPCR) to prevent a patent war. Genentech is paying $100M upfront + Royalties to Structure's subsidiary to secure "Freedom to Operate" for their oral GLP-1 CT-996. The Alpha: $GPCR Validation: Structure's "Patent Jungle" strategy worked. They just monetized a competitor's drug without spending a dime on its development. This is pure non-dilutive cash flow. Roche Conviction: You don't pay $100M "protection money" for a dead asset. This confirms Roche is doubling down on CT-996 despite the titration/side-effect noise from last"
X Link 2026-01-09T02:15Z [---] followers, [--] engagements
"BREAKING: Structure Therapeutics ($GPCR) just secured a massive "Freedom to Operate" payout from Roche ($RHHBY). Roche is paying $100M upfront + Royalties to license $GPCR patents for its own oral GLP-1 candidate (CT-996). The Alpha: Roche acquired Carmot for $2.7B but this deal implies $GPCR held critical IP cards blocking that asset. $GPCR now earns royalties on a key competitor's product while advancing their own pipeline ($100M non-dilutive cash). This validates the strength of Structures G-protein coupled receptor platform against big pharma scrutiny. Macro Backdrop: The "Patent War" is"
X Link 2026-01-11T02:15Z [---] followers, [---] engagements
"THE HOLY GRAIL: "In-vivo" CAR-T is officially heating up in China. While the West is hyped on $CABA and $KYTX curing Lupus with traditional (ex-vivo) CAR-T Fosun Kite (Gilead's China JV) just signaled a move to skip the manufacturing lab entirely. They are developing a Dual-Target In-vivo CAR-T for Autoimmune diseases (Lupus Myasthenia Gravis). The Mechanism: Instead of extracting patient blood shipping it and engineering it in a factory they use Antibody-conjugated LNPs (similar to mRNA vaccines) to reprogram T-cells directly inside the patient's body. The "Alpha" Claim: Fosun claims their"
X Link 2026-01-16T05:00Z [---] followers, [---] engagements
"Astellas is playing a dangerous game of chicken with a $6B Patent Cliff. Their blockbuster Xtandi loses exclusivity in [----]. Usually Big Pharma panics and buys a mid-cap to plug the revenue hole. Astellas CEO Okamura just said "No." No rescue M&A. Instead they are betting the house on [--] internal pillars: Padcev ($PFE): Now the standard of care in Bladder Cancer. They see $3.5B peak sales here. The CLDN18.2 Fortress: They aren't stopping at Vyloy (Zolbetuximab). They are advancing a proprietary ADC and a Bispecific to own the entire gastric cancer vertical. The Reality Check: It's not all"
X Link 2026-01-17T22:15Z [---] followers, [--] engagements
"ASCO GI 2026: Solid Tumor CAR-T is actually working. Everyone is watching Astellas ($ASTL) for CLDN18.2 antibodies. But a Chinese biotech ImmuneVance (Private) just posted Phase 1/2a CAR-T data that blows standard "late-stage" gastric cancer outcomes out of the water. The Asset: IMC002 (CLDN18.2 CAR-T). The Twist: It uses VHH Nanobodies (Camelid) instead of standard scFv. The Data (3rd Line+ Gastric Cancer): ORR: 66.7% (Massive for this indication) mOS: [----] months Safety: 0% Grade [--] CRS or ICANS. Why this matters: High toxicity usually kills Solid Tumor CAR-T programs. ImmuneVance just"
X Link 2026-01-19T02:15Z [---] followers, [---] engagements
"The King is Dead. Long Live the King. Gilead ($GILD) has officially lost the cell therapy crown. Johnson & Johnson ($JNJ) and Legend Biotech just reported the takeover numbers for FY2025: Carvykti Q4 Sales: $555M FY [----] Total: $1.89B (+96% YoY) [----] Forecast: $3B+ (Profitability Imminent) While Yescarta stalls Carvykti is doubling annually. Legend Biotech is now the owner of the #1 global CAR-T asset and is set to print operating profit in [----]. $LEGN $JNJ $GILD $XBI $IBB https://twitter.com/i/web/status/2014722312814395883 https://twitter.com/i/web/status/2014722312814395883"
X Link 2026-01-23T15:30Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing